BioVie Inc. (NASDAQ:BIVI) Short Interest Down 25.0% in April

BioVie Inc. (NASDAQ:BIVI) was the recipient of a large drop in short interest in April. As of April 15th, there was short interest totalling 1,110,000 shares, a drop of 25.0% from the March 31st total of 1,480,000 shares. Based on an average trading volume of 2,540,000 shares, the days-to-cover ratio is presently 0.4 days.

Institutional Investors Weigh In On BioVie

Several institutional investors have recently modified their holdings of BIVI. Jump Financial LLC acquired a new position in BioVie during the third quarter valued at approximately $34,000. Summit Trail Advisors LLC acquired a new position in BioVie during the third quarter valued at approximately $34,000. Finally, Crescent Grove Advisors LLC acquired a new position in BioVie during the third quarter valued at approximately $38,000. Institutional investors and hedge funds own 4.59% of the company’s stock.

BioVie Stock Up 2.1 %

Shares of NASDAQ:BIVI traded up $0.01 during trading on Monday, hitting $0.50. 1,130,037 shares of the company’s stock were exchanged, compared to its average volume of 2,084,630. BioVie has a 1-year low of $0.45 and a 1-year high of $8.69. The firm has a 50-day moving average price of $0.72 and a two-hundred day moving average price of $1.71.

BioVie (NASDAQ:BIVI) last issued its quarterly earnings results on Monday, February 12th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.10. On average, sell-side analysts forecast that BioVie will post -1 earnings per share for the current year.

BioVie Company Profile

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.